Core Viewpoint - Windtree Therapeutics, Inc. has received a non-binding letter of intent for the sale of its preclinical oncology aPKCi inhibitor platform, which includes an upfront payment of $7.0 million and potential milestone payments totaling up to $130.0 million, along with high single-digit royalties that could reach up to $1.5 billion over the drug's lifecycle [1][2][3]. Group 1 - The agreement allows for additional options to acquire the Company's cardiovascular clinical and preclinical stage drug candidates and includes a manufacturing agreement for Evofem Biosciences' FDA-approved product [2]. - The Company has a 21-day window to finalize the oncology aPKCi portion of the transaction [2]. - The CEO of Windtree stated that the preclinical oncology aPKCi assets are not viewed as core to the Company's future vision, but the transaction may provide non-dilutive cash and a lucrative revenue stream through milestones and royalties [3]. Group 2 - Windtree Therapeutics aims to become a revenue-generating company across multiple growing industries to achieve overall profitability [4].

Core Viewpoint - Windtree Therapeutics is pursuing a new corporate strategy focused on acquiring revenue-generating assets, including real estate and small biotech companies with FDA-approved products, while continuing to develop its therapeutic pipeline [1][2][3] Group 1: Acquisition and Revenue Generation - Windtree has entered into an agreement to acquire a 436-unit multifamily residential property in Houston, Texas, which is expected to provide consistent rental revenue [1] - The acquisition will be funded primarily through non-recourse secured mortgage financing, with additional funding from preferred stock issuance [1] - The company aims to diversify and stabilize its revenue streams through this acquisition, reducing reliance on capital that could dilute stock value [3] Group 2: Corporate Strategy and Pipeline Development - The new corporate strategy includes the acquisition of assets that contribute revenue while continuing the development of unique drug candidates in cardiovascular and oncology spaces [2][3] - Windtree's product candidates include istaroxime, a Phase 2 candidate for acute heart failure, and preclinical candidates for heart failure and oncology applications [4] - The company is actively seeking multiple acquisition candidates that could provide near-term revenue and profits [3]